$INM News
Last published 1d ago
- 1d agoINMInMed Pharmaceuticals Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 1.01 Item 2.01 Item 2.02 Item 3.02 Item 3.03 Item 5.01 Item 5.02 Item 5.03 Item 5.05 Item 5.06 Item 9.01
- 2d agoMTRIINMMentari Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mentari Therapeutics, Inc. (Nasdaq: MTRI), a clinical-stage biotechnology company developing therapies for migraine prevention, today announced that members of management will participate in the following upcoming investor conferences in November:
- 5d agoINMInMed Pharmaceuticals Completes Closing of Merger with Mentari TherapeuticsPR NewswireInMed Pharmaceuticals Inc. (which has changed its name to Mentari Therapeutics, Inc.) (NASDAQ: INM) ("Mentari" or the "Company") today...
- 2mo agoINMEarnings Call - INMED PHARMACEUTICALS INCEarnings Call Transcriptswelcome back everyone we are pleased to welcome sally washlow ceo of orion energy systems trading on the nasdaq under the ticker oesx and the cfo pair bordin now made in america for its fourth decade orion is meeting the
- 2mo agoINMEarnings Call - INMED PHARMACEUTICALS INCEarnings Call TranscriptsWelcome back everyone. Next we have SBC Medical Group Holdings Incorporated. It trades on the NASDAQ under the symbol SBC. It's a medical services organization providing management support across a wide range of healthca
- 2mo agoINMEarnings Call - INMED PHARMACEUTICALS INCEarnings Call TranscriptsCulture Inc. It trades on the OTC ID under the ticker FCUL. An Ontario-based brand and product development company focused on premium spirits, wine, and ready-to-drink beverages aligned with sports and entertainment mark
- 3mo agoINMMentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention PipelinePR NewswireMentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200...
- 3mo agoINMEarnings Call - INMED PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, good afternoon, or good evening, wherever this finds you. Welcome to the 94th Emerging Growth Conference and day two of our two-day virtual investor conference. I'm Anna Berry. Just a few notes. Today, we'r
- 4mo agoRKLBIRDMVSATINM+4Rocket Lab continues buying spree by acquiring satellite company IridiumTechCrunch
- 5mo agoINMEarnings Call - INMED PHARMACEUTICALS INCEarnings Call TranscriptsWelcome back, everyone. We have an update from Metavia Inc., trades on the NASDAQ under the symbol MTBA. It's a clinical stage biotech company focused on transforming cardiometabolic diseases. Happy to welcome President,
- 5mo agoINMEarnings Call - INMED PHARMACEUTICALS INCEarnings Call Transcriptsall right welcome back everyone we have an update from unusual machines inc trades on the new york stock exchange under the symbol umac and manufactures and sells drone components and drones across a diversified brand po
- 5mo agoINM/C O R R E C T I O N -- InMed Pharmaceuticals/PR NewswireInMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is pleased to announce that it has entered into a definitive merger agreement...
- 6mo agoINMEarnings Call - INMED PHARMACEUTICALS INCEarnings Call TranscriptsWe would like to welcome back Patrick Groon, CEO of Perpetuals.com, NASDAQ ticker PDC. Perpetuals is the AI-powered financial services company building infrastructure to level the playing field for retail traders. Patric
- 6mo agoINMEarnings Call - INMED PHARMACEUTICALS INCEarnings Call TranscriptsWelcome back, everyone. We have an update from Clean Inc. Trades on the NASDAQ under the symbol CLNN. It's a late clinical stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal
- 7mo agoINMEarnings Call - INMED PHARMACEUTICALS INCEarnings Call TranscriptsWe have Niocorp. They trade on the NASDAQ under the ticker NB. It's developing a critical minerals project in southeast Nebraska, focusing on producing niobium, scandium, and titanium plus rare earths. It is essential to
- 11mo agoBICXDTCFFECHQFGNVR+4Life Sciences Virtual Investor Forum Agenda Announced for December 11thGlobeNewswireNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th.
- 1y agoACUTDRMAHMTXFINM+4Life Sciences Virtual Investor Forum: Presentations Now Available for Online ViewingGlobeNewswireNEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held
- 1y agoINMInMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025GlobeNewswireCompany invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed
- 3y agoINMInMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business UpdateGlobeNewswireClosed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research using rare cannabinoids in treating glaucoma and neurodegenerative
- 3y agoGCTGHMGICGVA+25Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap ConferencesACCESS NewswireNEW YORK, NY / ACCESSWIRE / February 14, 2023 / Sidoti & Company, LLC announces that its two spring conferences are now open for registration. The March Virtual Small-Cap Conference will take place on Wednesday and
- 3y agoINMInMed Submits Form 12b-25GlobeNewswireVANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare
- 3y agoINMInMed Provides Business Update and Milestones for 2023GlobeNewswireComplete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in treating
- 3y agoINMInMed Announces Results of 2022 Annual General MeetingGlobeNewswireVANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare
- 3y agoINMInMed Announces Appointment of Interim Chief Financial Officer and Change of AuditorGlobeNewswireVANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare
- 3y agoINMInMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to MarketGlobeNewswireVANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare
- 3y agoINMInMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to MarketGlobeNewswireVANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare
- 3y agoINMInMed Provides Update on Management ChangesGlobeNewswireVANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare
- 3y agoINMInMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant FundingGlobeNewswireTargeting neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson'sIdentified two lead cannabinoid analog compounds for in vivo studiesNSERC grant funding supports InMed's collaborative research
- 4y agoINMInMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business UpdateGlobeNewswireVANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare
- 4y agoINMRegistration Now Open For Tribe Public's Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed's Management Team On November 17, 2022GlobeNewswireVANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare
- 4y agoINMInMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness WeekGlobeNewswireVANCOUVER, British Columbia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, announces
- 4y agoINMInMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business UpdateGlobeNewswireVANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, tod
- 4y agoINMInMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022GlobeNewswireVANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday,
- 4y agoINMInMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to MarketGlobeNewswireVANCOUVER, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced the closing of its previou
- 4y agoINMInMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to MarketGlobeNewswireVANCOUVER, British Columbia, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it has entered into a
- 4y agoINMInMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica BusinessGlobeNewswireVANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces an
- 4y agoINMInMed Announces Share Consolidation to Meet Nasdaq Listing CriteriaGlobeNewswireVANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces, pursuan
- 4y agoINMInMed Announces Changes to its Board of DirectorsGlobeNewswireVANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce t
- 4y agoINMInMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis BullosaGlobeNewswirePhase 2 clinical trial recently expanded to include adolescents following independent review of early safety data First adolescent patient with EB enrolled into clinical trial and completed treatment International patent granted for the use of cannab
- 4y agoINMInMed Announces Appointment of Chief Operating OfficerGlobeNewswireVANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael
- 4y agoINMInMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price ComplianceGlobeNewswireVANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a research, development, manufacturing corporation specializing in the commercialization of rare cannabinoids, announces
- 4y agoINMInMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin ConditionsGlobeNewswireVANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that a p
- 4y agoINMInMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness SectorGlobeNewswireProduces highly pure d9-dominant THCV, a non-intoxicating cannabinoid Bolsters Company's commercial portfolio, which also includes CBDV, CBC and CBT THCV has been researched for a variety of potential benefits VANCOUVER, British Columbia, June 09
- 4y agoINMInMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq RulesGlobeNewswireVANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the clos
- 4y agoINMInMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq RulesGlobeNewswireVANCOUVER, British Columbia, June 02, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it
- 4y agoINMInMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business UpdateGlobeNewswireExpands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication of a patent application for novel cannabinoid analogs Advances the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative dise
- 4y agoINMInMed to Supply Rare Cannabinoids to Radicle Science's "Radicle Energy Study" to Assess the Health Effects of THCVGlobeNewswireStudy will use delta-9 dominant THCV manufactured by InMed's subsidiary BayMedica Assesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on cannabinoids for consumers, brands and healthcare provi
- 4y agoINMInMed Pharmaceuticals (INM): Notable Launches of High-Value Rare CannabinoidsACCESS NewswireLONDON, UK / ACCESSWIRE / May 3, 2022 / InMed Pharmaceuticals (INM) continues its transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabino
- 4y agoINMInMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research ExpertGlobeNewswireExpands library of proprietary cannabinoid analogs for pharma R&D Research collaboration initiated to screen analogs for therapeutic uses VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- InMed Pharma
- 4y agoINMInMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness SectorGlobeNewswireExpands rare cannabinoid portfolio beyond current CBC and CBT Releases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- InMed Pha